JP2023542608A - グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用 - Google Patents

グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用 Download PDF

Info

Publication number
JP2023542608A
JP2023542608A JP2023507542A JP2023507542A JP2023542608A JP 2023542608 A JP2023542608 A JP 2023542608A JP 2023507542 A JP2023507542 A JP 2023507542A JP 2023507542 A JP2023507542 A JP 2023507542A JP 2023542608 A JP2023542608 A JP 2023542608A
Authority
JP
Japan
Prior art keywords
prostate cancer
subject
degradation
antagonist
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542608A5 (https=
Inventor
ジョウ，ハイイン
ダエメン，アンネレーン
バルクンド，シュラヴァニ
エス． フリードマン，ロリ
Original Assignee
オリック ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリック ファーマシューティカルズ，インク． filed Critical オリック ファーマシューティカルズ，インク．
Publication of JP2023542608A publication Critical patent/JP2023542608A/ja
Publication of JP2023542608A5 publication Critical patent/JP2023542608A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023507542A 2020-08-04 2021-08-03 グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用 Pending JP2023542608A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063061013P 2020-08-04 2020-08-04
US63/061,013 2020-08-04
US202163226102P 2021-07-27 2021-07-27
US63/226,102 2021-07-27
PCT/US2021/044255 WO2022031642A2 (en) 2020-08-04 2021-08-03 Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations

Publications (2)

Publication Number Publication Date
JP2023542608A true JP2023542608A (ja) 2023-10-11
JP2023542608A5 JP2023542608A5 (https=) 2024-07-30

Family

ID=80118471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507542A Pending JP2023542608A (ja) 2020-08-04 2021-08-03 グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用

Country Status (5)

Country Link
US (1) US20230302014A1 (https=)
EP (1) EP4192460A4 (https=)
JP (1) JP2023542608A (https=)
CN (1) CN116322694A (https=)
WO (1) WO2022031642A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US11285145B2 (en) 2020-05-27 2022-03-29 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
WO2024006527A1 (en) * 2022-07-01 2024-01-04 Arvinas Operations, Inc. Breast cancer treatment method
JP2025530798A (ja) * 2022-09-02 2025-09-17 コーセプト セラピューティクス， インコーポレイテッド エキシコリラントとエンザルタミドを用いて前立腺がんを治療する方法
WO2024092195A1 (en) * 2022-10-28 2024-05-02 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
WO2024220926A1 (en) * 2023-04-21 2024-10-24 Arvinas Operations, Inc. Use of an androgen receptor degrader protac for the treatment of prostate cancer
WO2024233696A1 (en) * 2023-05-09 2024-11-14 Arvinas Operations, Inc. Bavdegalutamide for treating prostate cancer without ar l702h mutation
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
EP3793541A4 (en) * 2018-05-16 2022-03-02 GTx, Inc. ANDROGEN RECEPTOR DEGRADER (SARD) SELECTIVE LIGANDS AND METHODS OF USE THEREOF

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AME MED. J., 2018, 3:66, DOI:10.21037/AMJ.2018.06.02, JPN6025032291, ISSN: 0005659051 *
CLIN. CANCER RES., 24(4), 2018, PP.927-938, JPN6025032290, ISSN: 0005659050 *
COMMUN. BIOL., 2018, 1:100, DOI:10.1038/S42003-018-0105-8, JPN6025032292, ISSN: 0005659052 *
J. CLIN. ONCOL., 2019, VOL.37, DOI:10.1200/JCO.2019.37.7_SUPPL.259, JPN6025032293, ISSN: 0005659053 *

Also Published As

Publication number Publication date
WO2022031642A3 (en) 2022-03-17
WO2022031642A2 (en) 2022-02-10
US20230302014A1 (en) 2023-09-28
CN116322694A (zh) 2023-06-23
EP4192460A2 (en) 2023-06-14
EP4192460A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
JP2023542608A (ja) グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用
Wu et al. Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells
US20210179660A1 (en) Glucocorticoid inhibitors for treatment of prostate cancer
ES2939940T3 (es) Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
Wardell et al. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
AU2022200059B2 (en) Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
Sp et al. The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts
Wróbel et al. Action of methyl-, propyl-and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells
Cheng et al. Curcumin-induced antitumor effects on triple-negative breast cancer patient-derived xenograft tumor mice through inhibiting salt-induced kinase-3 protein
Tafani et al. Up‐regulation of pro‐inflammatory genes as adaptation to hypoxia in MCF‐7 cells and in human mammary invasive carcinoma microenvironment
Ma et al. Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
Luo et al. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells
Yu et al. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression
Gu et al. Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells
WO2019054891A2 (en) ANTAGONISTS OF TRPV2
Ahrens et al. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity
Nishigaki et al. NDRG1 is expressed in human granulosa cells: An implicative role of NDRG1 in the ovary
WO2022192182A2 (en) USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST, ANTIANDROGEN, AND AKT INHIBITOR/PI3K INHIBITOR/mTOR INHIBITOR COMBINATIONS
Gao et al. Asperosaponin VI promotes progesterone receptor expression in decidual cells via the notch signaling pathway
Han et al. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma
Grant et al. DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC
Taghavi et al. Evaluating the expression pattern of the opioid receptor in pituitary neuroendocrine tumors (PitNET) and the role of morphine and naloxone in the regulation of pituitary cell line growth and apoptosis
EP3248604A1 (en) Agents for modulation of wnt-tcf signalling and uses thereof
Le Naour et al. The EO771 mammary cancer cell line displays a luminal B phenotype and it is sensitive to anti-estrogen treatments
US20120270799A1 (en) METHOD OF IDENTIFYING A CANDIDATE COMPOUND WHICH MAY INHIBIT a9-nAchR OVEREXPRESSION OR ESTROGEN RECEPTOR-DEPENDENT TRANSCRIPTION IN NICOTINE-DERIVED-COMPOUND-INDUCED BREAST CANCER CELLS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260128